Pathologic Complete Remission after Preoperative High-Dose-Rate Brachytherapy in Patients with Operable Cervical Cancer

Preliminary Results of a Prospective Randomized Multicenter Study

Julia Vízkeleti, Ildikó Vereczkey, Georgina Fröhlich, Szilvia Varga, Katalin Horváth, Tamás Pulay, Imre Pete, Csaba Nemeskéri, Árpád Mayer, Norbert Sipos, M. Kásler, C. Polgár

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The role of preoperative intrauterine brachytherapy (BT) in the multidisciplinary treatment of early stage cervical carcinoma (ESCC) is controversial. In 2005, a prospective randomized multicenter study was initiated in Hungary in order to explore the potential advantages of preoperative high-dose-rate (HDR) BT. In this article we evaluate the efficiency of preoperative HDR BT by the rate of pathologic complete remission (pCR) in the first 185 patients enrolled in the study at the National Institute of Oncology and at the Uzsoki Municipal Cancer Center in collaboration with the 1st Department of Gynaecology and Obstetrics of Semmelweis University, Budapest, Hungary. In arm A, patients received 2x8Gy preoperative intracavitary HDR BT, while in arm B no preoperative treatment was given. In both arms patients underwent radical Wertheim (Piver III) hysterectomy. The pCR rate was 25.7% after preoperative HDR BT, while it was only 11.2% with surgery alone (p=0.03), in these cases the tumor was eliminated during the diagnostic excision or conisation. The rate of positive surgical margins was 1.5% after preoperative BT, while it was as high as 11.4% without preoperative RT (p=0.02). There was no significant difference in the local tumor control (LTC), distant metastases free survival (DMFS) and overall survival (OS) between the two arms. According to our preliminary results preoperative intracavitary HDR BT significantly increases the rate of pCR and decreases the rate of positive surgical margins in patients with ESCC. Longer follow-up is required to establish the possible impact of pCR on the ultimate LTC and OS.

Original languageEnglish
Pages (from-to)247-256
Number of pages10
JournalPathology and Oncology Research
Volume21
Issue number2
DOIs
Publication statusPublished - Jul 11 2014

Fingerprint

Brachytherapy
Uterine Cervical Neoplasms
Multicenter Studies
Hungary
Survival
Neoplasms
Conization
Carcinoma
Hospital Obstetrics and Gynecology Department
Hysterectomy
Gynecology
Neoplasm Metastasis
Therapeutics

Keywords

  • Cervical cancer
  • Pathologic complete remission
  • Preoperative brachytherapy
  • Surgical margins

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pathology and Forensic Medicine

Cite this

Pathologic Complete Remission after Preoperative High-Dose-Rate Brachytherapy in Patients with Operable Cervical Cancer : Preliminary Results of a Prospective Randomized Multicenter Study. / Vízkeleti, Julia; Vereczkey, Ildikó; Fröhlich, Georgina; Varga, Szilvia; Horváth, Katalin; Pulay, Tamás; Pete, Imre; Nemeskéri, Csaba; Mayer, Árpád; Sipos, Norbert; Kásler, M.; Polgár, C.

In: Pathology and Oncology Research, Vol. 21, No. 2, 11.07.2014, p. 247-256.

Research output: Contribution to journalArticle

Vízkeleti, Julia ; Vereczkey, Ildikó ; Fröhlich, Georgina ; Varga, Szilvia ; Horváth, Katalin ; Pulay, Tamás ; Pete, Imre ; Nemeskéri, Csaba ; Mayer, Árpád ; Sipos, Norbert ; Kásler, M. ; Polgár, C. / Pathologic Complete Remission after Preoperative High-Dose-Rate Brachytherapy in Patients with Operable Cervical Cancer : Preliminary Results of a Prospective Randomized Multicenter Study. In: Pathology and Oncology Research. 2014 ; Vol. 21, No. 2. pp. 247-256.
@article{65050b49c5904fca94e23f1b29c026fc,
title = "Pathologic Complete Remission after Preoperative High-Dose-Rate Brachytherapy in Patients with Operable Cervical Cancer: Preliminary Results of a Prospective Randomized Multicenter Study",
abstract = "The role of preoperative intrauterine brachytherapy (BT) in the multidisciplinary treatment of early stage cervical carcinoma (ESCC) is controversial. In 2005, a prospective randomized multicenter study was initiated in Hungary in order to explore the potential advantages of preoperative high-dose-rate (HDR) BT. In this article we evaluate the efficiency of preoperative HDR BT by the rate of pathologic complete remission (pCR) in the first 185 patients enrolled in the study at the National Institute of Oncology and at the Uzsoki Municipal Cancer Center in collaboration with the 1st Department of Gynaecology and Obstetrics of Semmelweis University, Budapest, Hungary. In arm A, patients received 2x8Gy preoperative intracavitary HDR BT, while in arm B no preoperative treatment was given. In both arms patients underwent radical Wertheim (Piver III) hysterectomy. The pCR rate was 25.7{\%} after preoperative HDR BT, while it was only 11.2{\%} with surgery alone (p=0.03), in these cases the tumor was eliminated during the diagnostic excision or conisation. The rate of positive surgical margins was 1.5{\%} after preoperative BT, while it was as high as 11.4{\%} without preoperative RT (p=0.02). There was no significant difference in the local tumor control (LTC), distant metastases free survival (DMFS) and overall survival (OS) between the two arms. According to our preliminary results preoperative intracavitary HDR BT significantly increases the rate of pCR and decreases the rate of positive surgical margins in patients with ESCC. Longer follow-up is required to establish the possible impact of pCR on the ultimate LTC and OS.",
keywords = "Cervical cancer, Pathologic complete remission, Preoperative brachytherapy, Surgical margins",
author = "Julia V{\'i}zkeleti and Ildik{\'o} Vereczkey and Georgina Fr{\"o}hlich and Szilvia Varga and Katalin Horv{\'a}th and Tam{\'a}s Pulay and Imre Pete and Csaba Nemesk{\'e}ri and {\'A}rp{\'a}d Mayer and Norbert Sipos and M. K{\'a}sler and C. Polg{\'a}r",
year = "2014",
month = "7",
day = "11",
doi = "10.1007/s12253-014-9815-5",
language = "English",
volume = "21",
pages = "247--256",
journal = "Pathology and Oncology Research",
issn = "1219-4956",
publisher = "Springer Netherlands",
number = "2",

}

TY - JOUR

T1 - Pathologic Complete Remission after Preoperative High-Dose-Rate Brachytherapy in Patients with Operable Cervical Cancer

T2 - Preliminary Results of a Prospective Randomized Multicenter Study

AU - Vízkeleti, Julia

AU - Vereczkey, Ildikó

AU - Fröhlich, Georgina

AU - Varga, Szilvia

AU - Horváth, Katalin

AU - Pulay, Tamás

AU - Pete, Imre

AU - Nemeskéri, Csaba

AU - Mayer, Árpád

AU - Sipos, Norbert

AU - Kásler, M.

AU - Polgár, C.

PY - 2014/7/11

Y1 - 2014/7/11

N2 - The role of preoperative intrauterine brachytherapy (BT) in the multidisciplinary treatment of early stage cervical carcinoma (ESCC) is controversial. In 2005, a prospective randomized multicenter study was initiated in Hungary in order to explore the potential advantages of preoperative high-dose-rate (HDR) BT. In this article we evaluate the efficiency of preoperative HDR BT by the rate of pathologic complete remission (pCR) in the first 185 patients enrolled in the study at the National Institute of Oncology and at the Uzsoki Municipal Cancer Center in collaboration with the 1st Department of Gynaecology and Obstetrics of Semmelweis University, Budapest, Hungary. In arm A, patients received 2x8Gy preoperative intracavitary HDR BT, while in arm B no preoperative treatment was given. In both arms patients underwent radical Wertheim (Piver III) hysterectomy. The pCR rate was 25.7% after preoperative HDR BT, while it was only 11.2% with surgery alone (p=0.03), in these cases the tumor was eliminated during the diagnostic excision or conisation. The rate of positive surgical margins was 1.5% after preoperative BT, while it was as high as 11.4% without preoperative RT (p=0.02). There was no significant difference in the local tumor control (LTC), distant metastases free survival (DMFS) and overall survival (OS) between the two arms. According to our preliminary results preoperative intracavitary HDR BT significantly increases the rate of pCR and decreases the rate of positive surgical margins in patients with ESCC. Longer follow-up is required to establish the possible impact of pCR on the ultimate LTC and OS.

AB - The role of preoperative intrauterine brachytherapy (BT) in the multidisciplinary treatment of early stage cervical carcinoma (ESCC) is controversial. In 2005, a prospective randomized multicenter study was initiated in Hungary in order to explore the potential advantages of preoperative high-dose-rate (HDR) BT. In this article we evaluate the efficiency of preoperative HDR BT by the rate of pathologic complete remission (pCR) in the first 185 patients enrolled in the study at the National Institute of Oncology and at the Uzsoki Municipal Cancer Center in collaboration with the 1st Department of Gynaecology and Obstetrics of Semmelweis University, Budapest, Hungary. In arm A, patients received 2x8Gy preoperative intracavitary HDR BT, while in arm B no preoperative treatment was given. In both arms patients underwent radical Wertheim (Piver III) hysterectomy. The pCR rate was 25.7% after preoperative HDR BT, while it was only 11.2% with surgery alone (p=0.03), in these cases the tumor was eliminated during the diagnostic excision or conisation. The rate of positive surgical margins was 1.5% after preoperative BT, while it was as high as 11.4% without preoperative RT (p=0.02). There was no significant difference in the local tumor control (LTC), distant metastases free survival (DMFS) and overall survival (OS) between the two arms. According to our preliminary results preoperative intracavitary HDR BT significantly increases the rate of pCR and decreases the rate of positive surgical margins in patients with ESCC. Longer follow-up is required to establish the possible impact of pCR on the ultimate LTC and OS.

KW - Cervical cancer

KW - Pathologic complete remission

KW - Preoperative brachytherapy

KW - Surgical margins

UR - http://www.scopus.com/inward/record.url?scp=84938203990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938203990&partnerID=8YFLogxK

U2 - 10.1007/s12253-014-9815-5

DO - 10.1007/s12253-014-9815-5

M3 - Article

VL - 21

SP - 247

EP - 256

JO - Pathology and Oncology Research

JF - Pathology and Oncology Research

SN - 1219-4956

IS - 2

ER -